Tazarotene Completed Phase 3 Trials for Acne Vulgaris Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02267746A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
NCT03292640A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
NCT03290027A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
NCT02886715A Study Comparing Tazarotene Cream 0.1% to TAZORACĀ® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
NCT01017146A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
NCT01017120A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
NCT02160678Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris